Resumen
OBJECTIVE: Exacerbations of COPD requiring hospital admission have important clinical and societal implications. We sought to investigate the incidence, recurrence, risk factors, and mortality of patients with COPD exacerbations requiring hospital admission compared with those without hospital admission during 3-year follow-up. Patients with COPD (N=2,138) were identified from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) observational cohort. METHODS: An analysis of time to first event of hospital admission was performed using Kaplan-Meier curves and Cox proportional hazard regression adjusting for possible confounders. RESULTS: Of the 2,138 patients, 670 (31%) reported a total of 1,452 COPD exacerbations requiring hospital admission during the study period; 313 patients (15%) reported multiple events. A prior history ofexacerbation of COPD requiring hospital admission was the factor associated with the highest risk of a new hospitalization for exacerbation (hazard ratio, 2.71; 95% CI, 2.24-3.29; P <.001). Other risk factors included more severe airfl ow limitation, poorer health status, older age, radiologic evidence ofemphysema, and higher WBC count. Having been hospitalized for exacerbation significantly increased the risk of mortality (P , <001). CONCLUSIONS: Exacerbations of COPD requiring hospital admission occur across all stages of airfl ow limitation and are a significant prognostic factor ofreduced survival across all COPD stages. Patients with COPD at a high risk for hospitalization can be identified by their past history for similar events, and other factors, including the severity of airfl ow limitation, poor health status, age, presence ofemphysema, and leukocytosis.
Idioma original | English |
---|---|
Páginas (desde-hasta) | 999-1007 |
Número de páginas | 9 |
Publicación | Chest |
Volumen | 147 |
N.º | 4 |
DOI | |
Estado | Published - abr. 1 2015 |
Nota bibliográfica
Funding Information:Financial/nonfinancial disclosures: The authors have reported toCHESTthe following conflicts of interest: Drs Müllerova and Locantore are employed by and hold stock in GlaxoSmithKline plc, the study sponsor. Dr Vestbo has received consultation fees from AstraZeneca plc, Bioxydyn Ltd, Boehringer-Ingelheim GmbH, Chiesi Pharmaceuticals Inc, GlaxoSmithKline plc, Novartis AG, Pfizer Inc, and Takeda Pharmaceutical Co Ltd. He has also received lecture fees (including service on speakers bureaus) from AstraZeneca plc, Boehringer-Ingelheim GmbH, Chiesi Pharmaceuticals Inc, GlaxoSmithKline plc, Novartis AG, and Takeda Pharmaceutical Co Ltd; and research support from GlaxoSmithKline plc. His institution has received research from GlaxoSmithKline plc. He has also received an unconditional grant in 1985 from a charity foundation fully funded by Scandinavian Tobacco Company. Dr Vestbo's spouse has worked in the pharmaceutical industry, including GlaxoSmithKline plc. Dr Hurst has had support from GlaxoSmithKline plc to attend ECLIPSE meetings and has received payments for lectures and reports personal fees from AstraZeneca plc, Bayer AG, Boehringer-Ingelheim GmbH, Chiesi Pharmaceuticals Inc, GlaxoSmithKline plc, and Pfizer Inc. Dr Wedzicha has received honoraria for lectures and/or for serving on advisory boards from Almirall SA, Bayer AG, Boehringer-Ingelheim GmbH, Chiesi Pharmaceuticals Inc, GlaxoSmithKline plc, Novartis AG, Takeda Pharmaceutical Co Ltd, Pfizer Inc, and Vectura Group plc, and has obtained research grant funding for her department from Chiesi Pharmaceuticals Inc, GlaxoSmithKline plc, Novartis AG, Takeda Pharmaceutical Co Ltd, and Johnson and Johnson. Dr Bakke has received lecture fees from AstraZeneca plc, GlaxoSmithKline plc, and Nycomed International Management GmbH, and has participated in clinical research studies sponsored by Boehringer-Ingelheim GmbH, GlaxoSmithKline plc, and Pfizer Inc. Dr Agusti has received consulting fees, fees for participating in review activities, and support for travel from GlaxoSmithKline plc for this work, is a board member for Almirall SA, AstraZeneca plc, Boheringer-Ingelheim GmbH, Esteve, GlaxoSmithKline plc, Novartis AG, Nycomed International Management GmbH, and Roche (F. Hoffmann-La Roche AG), and has received payments for lectures and/or speaking from Almirall SA, AstraZeneca plc, Boheringer-Ingelheim GmbH, Esteve, GlaxoSmithKline plc, and Nycomed International Management GmbH; and his institution has received grants from Almirall SA, GlaxoSmithKline plc, and Nycomed International Management GmbH. Dr Anzueto is a consultant and speaker for AstraZeneca plc, Bayer AG, Boehringer-Ingleheim GmbH, Forest Laboratories Inc, and GlaxoSmithKline plc. Dr Maselli has reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
Publisher Copyright:
© 2015 American College of Chest Physicians.
ASJC Scopus Subject Areas
- Pulmonary and Respiratory Medicine
- Critical Care and Intensive Care Medicine
- Cardiology and Cardiovascular Medicine